Janus Henderson Group PLC Has $30.31 Million Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Janus Henderson Group PLC lifted its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 18.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,177,197 shares of the company's stock after buying an additional 337,928 shares during the period. Janus Henderson Group PLC owned about 2.16% of Day One Biopharmaceuticals worth $30,307,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of DAWN. FMR LLC raised its holdings in Day One Biopharmaceuticals by 178.5% during the third quarter. FMR LLC now owns 7,412,380 shares of the company's stock worth $103,254,000 after acquiring an additional 4,750,936 shares in the last quarter. Braidwell LP raised its stake in shares of Day One Biopharmaceuticals by 60.5% during the 3rd quarter. Braidwell LP now owns 4,873,853 shares of the company's stock worth $67,893,000 after purchasing an additional 1,837,949 shares in the last quarter. Vestal Point Capital LP boosted its holdings in shares of Day One Biopharmaceuticals by 100.0% in the 3rd quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company's stock valued at $34,825,000 after buying an additional 1,250,000 shares during the last quarter. Deerfield Management Company L.P. Series C grew its stake in shares of Day One Biopharmaceuticals by 65.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company's stock valued at $40,281,000 after buying an additional 1,157,825 shares in the last quarter. Finally, First Turn Management LLC acquired a new position in Day One Biopharmaceuticals during the third quarter worth $13,204,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DAWN has been the subject of a number of recent analyst reports. TD Cowen upgraded shares of Day One Biopharmaceuticals to a "strong-buy" rating in a research note on Monday, November 4th. HC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Day One Biopharmaceuticals has a consensus rating of "Buy" and an average target price of $35.71.

Day One Biopharmaceuticals Trading Up 2.2 %

NASDAQ DAWN traded up $0.29 during trading on Friday, reaching $13.75. The company's stock had a trading volume of 568,170 shares, compared to its average volume of 1,086,949. The firm has a 50 day moving average price of $14.27 and a 200 day moving average price of $14.07. Day One Biopharmaceuticals, Inc. has a 12 month low of $11.51 and a 12 month high of $18.07. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of -13.35 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.58. The company had revenue of $93.76 million during the quarter, compared to the consensus estimate of $15.05 million. During the same quarter last year, the firm posted ($0.54) earnings per share. On average, equities analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.88 EPS for the current fiscal year.

Insider Activity

In other news, insider Samuel C. Blackman sold 10,000 shares of the business's stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $16.10, for a total value of $161,000.00. Following the completion of the transaction, the insider now directly owns 1,057,535 shares in the company, valued at approximately $17,026,313.50. The trade was a 0.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders sold 51,745 shares of company stock worth $775,867. 8.40% of the stock is currently owned by company insiders.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.